S

SK Biopharmaceuticals
A326030

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
₩7.20T
EV
₩7.08T
Shares Outstanding
78.31M
Beta
0.85

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
₩138066.67
P/E 2025E
53.13x
P/Revenue 2025E
10.32x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About SK Biopharmaceuticals Co., Ltd.

gainify

S

SK Biopharmaceuticals Co., Ltd.

A326030

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol...

Sector

Healthcare

Industry

Biotechnology

CEO

Lee, Dong Hoon

Employees

241

IPO Date

2020-07-02

Headquarters

221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, South Korea

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.